advanc
techniqu
field
diagnost
microbiolog
made
amaz
progress
past
year
due
larg
technolog
revolut
molecular
aspect
microbiolog
particular
rapid
molecular
method
nucleic
acid
amplif
character
combin
autom
clinic
microbiolog
laboratori
well
userfriendli
softwar
robust
laboratori
informat
system
significantli
broaden
diagnost
capabl
modern
clinic
microbiolog
laboratori
molecular
method
nucleic
acid
amplif
test
naat
rapidli
develop
introduc
clinic
laboratori
set
inde
everi
section
clinic
microbiolog
laboratori
includ
bacteriolog
mycolog
mycobacteriolog
parasitolog
virolog
benefit
advanc
techniqu
rapid
develop
adapt
molecular
techniqu
interpret
relev
result
produc
molecular
method
continu
lag
behind
purpos
chapter
review
updat
discuss
interpret
relev
result
produc
advanc
molecular
techniqu
detect
circul
microbi
dna
ie
dnaemia
per
se
new
diagnost
paramet
may
may
repres
presenc
viabl
microorgan
blood
exampl
interpret
dnaemia
coagulaseneg
staphylococci
problemat
due
falseposit
rate
rang
contrast
interpret
dnaemia
ehrlichia
speci
problem
due
trueposit
rate
interpret
dnaemia
also
problem
studi
dnaemia
detect
pcr
blood
cultur
number
falseposit
pcr
result
consid
clinic
signific
base
either
retrospect
chart
review
subsequ
isol
pathogen
relev
clinic
specimen
clearli
continu
clinic
investig
microbi
dnaemia
sepsi
critic
ill
need
provid
better
understand
biolog
microbi
circul
dna
underpin
molecular
diagnost
techniqu
anoth
import
issu
molecular
diagnost
techniqu
need
molecular
detect
resist
determin
antimicrobi
suscept
test
recogn
import
confirm
suscept
chosen
empir
antimicrobi
agent
well
detect
resist
individu
microbi
isol
current
method
antimicrobi
suscept
test
continu
base
part
detect
microbi
growth
lack
growth
presenc
antimicrobi
agent
test
direct
detect
resist
gene
molecular
method
pcr
molecular
probe
date
limit
due
fact
rel
resist
gene
firmli
associ
phenotyp
resist
exampl
resist
gene
associ
phenotyp
resist
found
gramposit
cocci
includ
meca
vana
vanb
contrast
lack
consensu
sequenc
among
acetyltransferas
adenyltransferas
gene
gramneg
bacilli
make
molecular
detect
aminoglycosid
resist
difficult
although
molecular
method
antimicrobi
suscept
test
improv
phenotyp
method
determin
level
suscept
bacteri
isol
antimicrobi
agent
continu
remain
clinic
relev
volum
blood
cultur
known
import
variabl
blood
cultur
number
microorgan
blood
may
small
typic
adult
fewer
cfuml
may
less
cfuml
septic
neonat
sizeabl
subset
less
cfuml
clearli
volum
blood
test
molecular
method
also
import
moreov
poisson
distribut
microorgan
evenli
distribut
increas
likelihood
sampl
small
volum
blood
miss
microorgan
caus
sepsi
volumerel
issu
may
explain
lower
sensit
seen
molecular
method
seen
convent
blood
cultur
studi
neonat
sepsi
poisson
distribut
may
explain
moder
concord
blood
cultur
molecular
method
report
studi
postsurg
sepsi
adult
sampl
blood
collect
assess
bacteremia
andor
fungemia
whether
analysi
done
blood
cultur
molecular
method
contamin
microorgan
skin
venipunctur
transient
bacteremia
andor
indwel
vascular
devic
blood
obtain
devic
falseposit
blood
cultur
due
contamin
recogn
troublesom
issu
decad
contamin
less
import
molecular
method
current
number
differ
molecular
assay
detect
presenc
tuberculosi
sputum
includ
pcr
transcriptionmedi
amplif
loopmedi
isotherm
amplif
simultan
amplif
test
xpert
mtbrif
comparison
mycobacteri
cultur
molecular
assay
possess
sensit
approach
exceed
gener
molecular
method
work
better
smearposit
smearneg
sputum
specimen
none
sensit
mycobacteri
cultur
sensit
patient
smearneg
sputum
increas
use
bronchial
aspir
bronchial
lavag
fluid
still
sensit
mycobacteri
cultur
naat
detect
microbi
organismspecif
nucleic
acid
therefor
posit
naat
result
result
live
dead
microorgan
particularli
true
mycobacteria
thick
wax
cell
wall
best
exampl
detect
tuberculosi
dna
sputum
dead
microbi
pathogen
dna
remain
undegrad
due
fatti
acidrich
cell
wall
unlik
result
functionbas
test
method
mycobacteri
cultur
clinic
set
posit
pcr
result
antituberculosi
therapi
necessarili
mean
treatment
failur
applic
mrnatarget
naat
demonstr
monitor
tuberculosi
therapi
antitb
therapi
regimen
select
larg
empir
treatment
may
modifi
week
month
later
result
antimicrobi
suscept
test
becom
avail
halflif
bacteri
mrna
extrem
short
compar
rrna
genom
dna
molecular
assay
target
mycobacteri
mrna
better
reflect
mycobacteri
viabil
abil
mrnabas
assay
distinguish
viabl
nonviabl
organ
demonstr
assay
use
monitor
efficaci
antitb
therapi
current
number
differ
molecular
assay
detect
gene
mutat
associ
resist
particular
antituberculosi
drug
alway
gap
basic
research
clinic
applic
drug
resist
mechan
remain
unknown
new
resistancerel
mutat
emerg
addit
molecular
assay
basic
includ
dna
amplif
step
categor
manner
amplifi
dna
detect
except
sequenc
distinct
advantag
method
none
method
includ
sequenc
abl
detect
resist
strain
although
sequenc
come
closest
major
limit
molecular
method
except
sequenc
detect
known
mutat
defin
site
region
design
depend
upon
known
mutat
advantag
sequenc
molecular
detect
mutat
drug
resist
seen
report
center
diseas
control
prevent
studi
use
dna
sequenc
detect
resist
firstlin
antituberculosi
drug
isoniazid
rifampin
pyrazinamid
ethambutol
secondlin
drug
amikacin
capreomycin
kanamycin
ciprofloxacin
ofloxacin
molecular
data
compar
phenotyp
data
sensit
specif
valu
firstlin
secondlin
drug
loci
gener
excel
support
use
dna
sequenc
detect
drug
resist
tuberculosi
complex
although
uncommon
misidentif
report
molecular
assay
tuberculosi
one
report
case
patient
present
inguin
lymphadenopathi
well
erythema
nodosumlik
lesion
leg
forearm
biopsi
enlarg
inguin
lymph
node
demonstr
caseat
granulomata
numer
acidfast
bacilli
ziehlneelsen
stain
portion
node
sent
mycobacteri
cultur
molecular
analysi
addit
skin
biopsi
forearm
nodul
done
reveal
acidfast
bacilli
morpholog
typic
mycobacterium
lepra
diagnosi
leprosi
made
base
clinic
present
skin
biopsi
result
howev
lymph
node
sent
mycobacteri
cultur
molecular
analysi
posit
genprob
amplifi
mycobacterium
tuberculosi
direct
mtd
test
although
leprosi
still
consid
correct
diagnosi
due
clinic
present
skin
biopsi
find
possibl
patient
also
tuberculosi
could
rule
cultur
result
known
therefor
patient
treat
leprosi
tuberculosi
cultur
week
well
addit
pcr
test
lymph
node
materi
tuberculosi
report
neg
root
caus
analysi
done
order
investig
misidentif
lepra
cultur
materi
obtain
nation
hansen
diseas
program
louisiana
state
univers
mycobacteri
organ
test
genprob
mtd
test
posit
concentr
organ
per
ml
indetermin
concentr
organ
per
ml
investig
conclud
high
concentr
lepra
clinic
specimen
could
lead
falseposit
result
genprob
mtd
test
lepra
also
misidentifi
intracellular
coba
amplicor
intracellular
test
clearli
limit
convent
sputum
cultur
method
diagnos
respiratori
tract
infect
also
limit
molecular
method
particular
collect
sputum
continu
import
aspect
diagnosi
lower
respiratori
tract
infect
even
molecular
assay
use
new
molecular
method
guarante
microbiolog
laboratori
receiv
optim
sputum
sampl
analyz
anoth
import
aspect
molecular
assay
diagnosi
respiratori
infect
method
begun
reveal
complex
pulmonari
microbiom
inde
recent
applic
molecular
assay
reveal
divers
microbiota
previous
recogn
airway
patient
chronic
pulmonari
diseas
exampl
comprehens
profil
airway
bacteri
commun
accomplish
use
cultureindepend
microarray
rrna
phylochip
cohort
copd
patient
requir
ventilatori
support
antimicrobi
therapi
exacerbationrel
respiratori
failur
phylochip
analysi
demonstr
presenc
bacteri
taxa
repres
distinct
famili
includ
mani
previous
detect
airway
diseas
core
commun
bacteri
taxa
note
patient
mani
microorgan
known
pathogen
airway
diseas
given
fact
pulmonari
microbiom
complex
previous
appreci
obviou
question
becom
microorgan
colon
caus
infect
one
might
also
ask
real
differ
colon
infect
airway
molecular
identif
bacteria
lower
airway
preterm
infant
reveal
earli
bacteri
colon
airway
divers
speci
occur
within
first
day
life
intub
preterm
infant
neonat
airway
colon
gramneg
bacilli
associ
cytokin
respons
well
sever
bronchopulmonari
dysplasia
etiolog
role
neonat
colon
children
noncyst
fibrosi
bronchiectasi
unclear
time
molecular
method
provid
insight
pathogenesi
bronchopulmonari
dysplasia
infant
similarli
etiolog
role
bacteri
colon
pathogenesi
chronic
obstruct
pulmonari
diseas
current
elucid
assist
molecular
method
extrem
sensit
molecular
method
naat
may
result
simultan
detect
multipl
pathogen
sputum
specimen
detect
multipl
pathogen
sputum
molecular
method
alreadi
report
communityacquir
pneumonia
mix
infect
frequent
seen
commonli
streptococcu
pneumonia
togeth
respiratori
viru
find
unexpect
number
studi
report
associ
viral
respiratori
tract
infect
invas
pneumococc
diseas
molecular
diagnost
method
employ
studi
respiratori
tract
infect
confirm
etiolog
role
viral
respiratori
tract
infect
bacteri
pneumonia
respiratori
sampl
cyclethresholdvaluebas
semiquantit
interpret
qpcr
result
suggest
etiolog
relev
assum
cyclethreshold
valu
low
suggest
high
pathogen
load
import
issu
naat
whether
amplif
product
truli
repres
target
microorgan
molecular
method
employ
dna
sequenc
often
consid
complet
accur
sensit
specif
unfortun
case
varieti
technic
factor
influenc
contamin
dna
sourc
sequenc
templat
select
primer
use
amplif
qualiti
basecal
softwar
method
use
compil
consensu
sequenc
multipl
forward
revers
reaction
inappropri
chosen
gene
target
region
result
fals
posit
neg
insert
sequenc
element
found
sever
hundr
copi
b
pertussi
genom
frequent
use
target
b
pertussi
detect
much
greater
analyt
sensit
assay
singlecopi
target
sequenc
pertussi
toxin
promot
howev
falseposit
result
report
due
smaller
copi
number
exist
nonpertussi
bordetella
speci
accuraci
assay
develop
often
appreci
nonmolecular
microbiologist
clinician
absenc
gold
standard
microbiolog
caus
symptomat
enter
infect
mean
clinic
signific
detect
pathogen
may
alway
clear
although
convent
wisdom
suggest
one
main
pathogen
caus
symptomat
enter
infect
patient
detect
multipl
pathogen
patient
challeng
think
question
stool
colon
potenti
pathogen
versu
pathogen
truli
caus
gastroenter
difficult
apt
particularli
true
parasit
enter
infect
moreov
detect
rna
dna
stool
specimen
necessarili
mean
viabl
pathogen
pathogen
truli
caus
gastroenter
molecular
assay
includ
highthroughput
sequenc
techniqu
begun
identifi
vast
commun
bacteria
inhabit
skin
gut
human
despit
method
human
gut
remain
rel
unexplor
complex
continu
factor
use
naat
diagnos
enter
infect
reason
influenc
contamin
dna
gut
microb
sequenc
templat
molecular
diagnosi
enter
infect
usual
begin
extract
nucleic
acid
specimen
specimen
gener
diarrheal
stool
sampl
extract
step
becom
critic
step
molecular
diagnost
process
stool
complex
mixtur
multipl
divers
nucleic
acid
amplif
inhibitor
investig
note
detect
given
target
reduc
sever
log
target
place
stool
mixtur
may
result
enter
pathogen
present
low
number
miss
reason
investig
use
mass
spectrometri
identif
method
follow
isol
potenti
enter
bacteri
pathogen
stool
addit
extract
dna
ova
parasit
may
difficult
extract
dna
bacteria
concentr
ova
parasit
may
present
low
number
may
requir
microscop
evalu
parasit
pathogen
current
recogn
potenti
caus
enter
infect
mean
multiplex
pcr
luminex
bead
method
filmarray
realtim
pcr
assay
must
use
even
multiplex
approach
like
requir
use
diagnost
algorithm
use
sever
multiplex
assay
use
multiplex
assay
creat
sever
technic
problem
includ
difficulti
discrimin
multipl
target
singl
reaction
reduc
sensit
multiplex
assay
also
caus
problem
interpret
due
detect
multipl
pathogen
exampl
one
studi
reexamin
stool
sampl
use
pcr
found
detect
rate
increas
viral
bacteri
pathogen
detect
rate
multipl
pathogen
also
increas
similar
respiratori
specimen
etiolog
relev
assum
cyclethreshold
valu
qpcr
result
low
correl
high
pathogen
load
molecular
assay
due
high
sensit
may
detect
low
level
enter
pathogen
unclear
clinic
signific
exampl
giardia
speci
known
occur
stool
high
rate
person
without
diarrhea
recent
studi
reveal
high
level
noroviru
fecal
load
correl
noroviru
genogroup
ii
infect
associ
develop
sever
clinic
symptom
time
diagnosi
therefor
use
quantit
pcr
method
may
need
order
provid
inform
use
interpret
clinic
signific
assumpt
higher
burden
like
associ
diseas
ultim
relationship
higher
burden
symptom
diseas
need
verifi
mani
enter
pathogen
relationship
yet
determin
antimicrobi
resist
increas
mani
bacteri
pathogen
like
happen
enter
pathogen
shigella
salmonella
campylobact
detect
resist
determin
may
necessari
futur
like
difficult
stool
sampl
due
divers
microorgan
present
stool
realtim
pcrbase
monoplex
assay
provid
excel
qualif
procedur
wide
rang
concentr
cover
howev
assay
ideal
qualit
measur
object
criteria
determin
cutoff
point
problemat
microbi
load
test
specimen
extrem
low
exampl
hsv
chlamydia
pneumonia
detect
csf
specimen
realtim
pcr
object
sensit
comparison
end
detect
pcr
procedur
neg
filmarray
panel
result
exclud
infect
due
organ
includ
panel
falseneg
result
target
pathogen
present
low
quantiti
still
possibl
empir
antibiot
andor
acyclovir
still
administ
clinic
suspicion
bacteri
infect
hsv
enceph
high
despit
neg
meningitisenceph
panel
although
multiplex
pcrbase
assay
filmarray
panel
offer
promis
syndrom
platform
rapid
diagnosi
cn
infect
mani
falseposit
unconfirm
panel
result
note
comprehens
list
target
includ
panel
ensur
action
diagnosi
like
miss
falseposit
result
problemat
streptococcu
pneumonia
frequent
falseposit
detect
made
panel
clinic
irrelev
posit
detect
h
influenza
also
reveal
institut
tang
unpublish
data
falseposit
csf
test
result
potenti
result
signific
harm
lead
unnecessari
potenti
toxic
antimicrobi
therapi
unwarr
invas
procedur
sever
falseposit
panel
result
publish
studi
theoret
could
untoward
sequela
therapi
invas
procedur
implement
observ
highlight
import
laboratori
oper
procedur
design
minim
carryov
contamin
even
use
close
system
filmarray
oper
wear
mask
load
filmarray
pouch
andor
ideal
use
biolog
safeti
cabinet
dead
air
box
laboratori
must
establish
expect
posit
rate
individu
target
contain
panel
order
monitor
contamin
final
interpret
clinic
signific
reactiv
latent
herpesvirida
difficult
provid
must
consid
result
care
clinic
context
exampl
syndrom
nucleic
acid
amplif
test
panel
filmarray
system
simultan
detect
broad
rang
pathogen
improv
diagnosi
mani
infecti
diseas
reduc
turnaround
time
simplifi
laboratori
workflow
rapid
result
obtain
use
guid
antimicrobi
therapi
improv
infect
prevent
practic
howev
system
detect
multipl
microorgan
may
difficult
determin
microorgan
caus
clinic
infect
particularli
import
real
pathogen
miss
like
due
low
test
sensit
differ
microorgan
detect
exampl
gomez
et
al
describ
case
tubercul
mening
misdiagnos
herp
simplex
enceph
use
filmarray
panel
syndrom
diagnost
panel
one
stone
two
bird
becom
popular
wide
use
clinic
practic
laboratorian
face
guid
ration
use
expens
technolog
current
absenc
studi
evalu
costeffect
fda
approv
necessarili
mean
panel
go
right
approach
patient
cn
infect
sever
factor
consid
implement
panel
first
patient
test
pathogen
target
panel
appropri
immunocompromis
patient
cn
infect
set
member
herpesvirida
well
cryptococcu
speci
commonli
seen
caus
signific
diseas
pediatr
adult
patient
acut
mening
high
clinic
suspicion
bacteri
infect
panel
could
reduc
time
diagnosi
may
particularli
use
situat
patient
receiv
empir
antimicrobi
therapi
prior
diagnost
lumbar
punctur
short
select
situat
target
molecular
test
priorit
like
pathogen
first
consider
laboratori
screen
criteria
base
part
csf
nucleat
cell
count
might
way
minim
unnecessari
test
immunocompet
adult
argu
perform
target
molecular
test
base
clinic
suspicion
like
costeffect
immunocompet
patient
especi
test
done
inhous
summari
panel
appear
addit
test
necessarili
replac
current
approach
freshfrozen
tissu
best
molecular
test
avail
molecular
test
consid
time
biopsi
contrast
ffpe
tissu
usual
avail
often
tissu
avail
molecular
test
consid
afterthought
accordingli
one
import
limit
use
molecular
assay
diagnos
tissu
infect
consid
assay
time
biopsi
fresh
tissu
use
frozen
use
later
differ
sensit
pcr
test
seen
studi
fresh
nonembed
tissu
found
sensit
pcr
detect
fungi
versu
ffpe
tissu
reason
decreas
sensit
nucleic
acid
obtain
ffpe
tissu
frequent
damag
ie
crosslink
may
contain
pcr
inhibitor
ffpe
tissu
must
use
housekeep
human
gene
must
amplifi
control
wide
divers
potenti
microbi
pathogen
could
potenti
detect
tissu
readili
appar
pathogen
could
viral
bacteri
fungal
parasit
divers
greatli
influenc
dna
target
pcr
primer
use
well
whether
monoplex
multiplex
pcr
method
use
exampl
speciesspecif
identif
wide
rang
clinic
relev
fungal
pathogen
use
luminex
technolog
requir
three
differ
probe
fungal
pathogen
use
intern
transcrib
spacer
region
highli
variabl
among
genom
individu
fungal
speci
choic
dna
target
import
gener
molecular
assay
target
multicopi
gene
provid
greatest
sensit
amplif
method
provid
object
endpoint
assess
pdr
test
use
pcr
primer
import
exampl
insuffici
variat
intern
transcrib
spacer
region
differenti
certain
speci
fungal
pathogen
therefor
analysi
region
consid
falseposit
result
describ
certain
primer
h
capsulatum
falseneg
result
found
c
immiti
ffpe
tissu
sensit
versu
fresh
tissu
sensit
suggest
primer
problem
degrad
inhibitor
final
estim
approxim
sequenc
genbank
misidentifi
current
rel
commerci
kit
avail
molecular
test
use
tissu
specimen
laboratorydevelop
pcr
assay
tissu
use
must
evalu
verifi
valid
laboratori
result
use
clinic
diagnosi
patient
care
dna
extract
ffpe
tissu
difficult
requir
special
protocol
amount
dna
extract
usual
quit
small
report
method
show
amplif
success
rate
commerci
dna
extract
kit
evalu
one
method
takara
note
extract
dna
ffpe
tissu
sampl
housekeep
gene
could
amplifi
moreov
method
costeffect
nonlabori
protocol
success
extract
rna
ffpe
specimen
depend
prompt
origin
tissu
process
welldevelop
extract
protocol
number
pathogen
scant
tissu
amount
dna
obtain
may
insuffici
perform
pcr
assay
moreov
pathogen
often
randomli
distribut
tissu
ffpe
tissu
use
punch
biopsi
use
take
sampl
area
note
inflamm
andor
microorgan
stain
slide
tissu
block
stain
slide
mark
use
direct
locat
punch
biopsi
sampl
tissu
block
use
fresh
frozen
tissu
problemat
select
tissu
random
may
contain
microorgan
would
expect
molecular
assay
alreadi
note
detect
mix
infect
may
present
difficulti
interpret
result
particular
microbi
divers
endocard
note
cultivationindepend
molecular
techniqu
multipl
pathogen
detect
molecular
assay
also
report
fungal
infect
outcom
infecti
diseas
often
depend
earli
appropri
antimicrobi
therapi
appropri
antimicrobi
therapi
directli
relat
length
time
requir
identif
microbi
pathogen
recent
clinic
microbiolog
laboratori
handicap
convent
slow
multistep
culturebas
techniqu
requir
prolong
incub
time
mani
pathogen
abl
isol
other
clinician
unabl
clinic
judgment
diagnost
result
quickli
accur
identifi
pathogen
caus
infect
must
adopt
conserv
approach
involv
empir
therapi
broadspectrum
antimicrobi
agent
fortun
cumbersom
approach
rapidli
chang
last
two
decad
increas
util
molecular
diagnost
techniqu
inde
molecular
assay
naat
initi
revolut
field
diagnost
microbiolog
due
high
sensit
specif
rapid
test
turnaround
time
well
potenti
high
throughput
autom
particular
emerg
commerci
molecular
test
diagnosi
bloodstream
infect
promis
improv
patient
outcom
septic
patient
adapt
molecular
syndrom
method
microbiolog
diagnost
pointofcar
laboratori
also
promis
improv
patient
outcom
molecular
assay
herald
diagnost
tool
millennium
howev
molecular
assay
also
bring
uncertainti
caus
falseposit
result
due
contamin
endogen
exogen
sourc
dna
exampl
one
studi
use
univers
rrna
pcr
assay
detect
eubacteri
dna
blood
sampl
healthi
subject
naat
also
may
give
falseneg
result
due
two
principl
reason
rel
small
sampl
requir
pcr
reaction
technic
problem
associ
pcr
process
moreov
result
molecular
assay
may
difficult
interpret
appli
clinic
set
naat
increasingli
use
routin
clinic
microbiolog
laboratori
interpret
expect
difficult
new
test
develop
complic
multiplex
assay
emerg
exampl
clinic
relev
posit
naat
paraffin
block
specimen
multipl
microbi
organ
found
specimen
need
care
interpret
use
molecular
assay
determin
usag
time
commun
clinician
microbiolog
laboratori
alway
suggest
increasingli
import
whenev
interpret
need
final
clinic
microbiologist
clinician
must
acquir
work
knowledg
principl
diagnost
valu
limit
molecular
assay
